Jennifer Lynne Fox Emergent Bio Solutions Inc. (EBS) insider trading activity

Jennifer Lynne Fox is EVP, Ext Aff, GC, Corp Sec of Emergent BioSolutions Inc.. Currently has a direct ownership of 186,382 shares of EBS, which is worth approximately $1.69 Million. The most recent transaction as insider was on Jul 11, 2024, when has been sold 15,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 186K

0% 3M change

4.0% 12M change

Total Value Held $1.69 Million

Jennifer Lynne Fox Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 11 2024	BUY Grant, award, or other acquisition	-	15,000 Added 7.45%	186,382 Common Stock
Jun 08 2024	SELL Payment of exercise price or tax liability	$14,707 $6.19 p/Share	2,376 Reduced 1.37%	171,382 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$2,383 $3.39 p/Share	703 Reduced 0.4%	173,758 Common Stock
Feb 29 2024	SELL Payment of exercise price or tax liability	$13,252 $3.23 p/Share	4,103 Reduced 2.3%	174,461 Common Stock
Feb 23 2024	SELL Payment of exercise price or tax liability	$627 $2.74 p/Share	229 Reduced 0.13%	178,564 Common Stock
Nov 11 2023	SELL Payment of exercise price or tax liability	$826 $2.0 p/Share	413 Reduced 0.23%	178,793 Common Stock
Jun 09 2023	BUY Grant, award, or other acquisition	-	73,847 Added 29.18%	179,206 Common Stock
Mar 02 2023	BUY Grant, award, or other acquisition	-	18,462 Added 14.91%	105,359 Common Stock
Feb 28 2023	SELL Payment of exercise price or tax liability	$12,441 $12.38 p/Share	1,005 Reduced 1.14%	86,897 Common Stock
Feb 24 2023	SELL Payment of exercise price or tax liability	$3,537 $13.71 p/Share	258 Reduced 0.29%	87,902 Common Stock
Feb 23 2023	SELL Payment of exercise price or tax liability	$3,303 $14.3 p/Share	231 Reduced 0.26%	88,160 Common Stock
Dec 09 2022	BUY Grant, award, or other acquisition	-	56,180 Added 38.86%	88,391 Common Stock
Nov 11 2022	SELL Payment of exercise price or tax liability	$6,240 $15.0 p/Share	416 Reduced 1.28%	32,211 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	25,377 Added 43.75%	32,627 Common Stock

Also insider at

MYGN

MYRIAD GENETICS INC Healthcare

Chief Legal Officer

JLF